GLP-1 Drugs Linked to Unexpected Pregnancies, Raising Fertility Concerns

A Surprising Pattern Emerges

Across the United States and in other countries, a quiet but growing number of women are reporting a startling phenomenon: unintended pregnancies while taking GLP-1 receptor agonists—medications commonly prescribed for type 2 diabetes and chronic weight management. These reports, which have circulated through patient forums and clinical discussions, involve women who had struggled with infertility for years, as well as those who were consistently using oral contraceptives. The common thread is a GLP-1 drug such as semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda), and the unexpected appearance of a positive pregnancy test.

While these accounts are largely anecdotal, they have captured the attention of endocrinologists, obstetricians, and drug regulators. The underlying mechanisms are not yet fully understood, but doctors point to two primary factors: the profound metabolic changes induced by rapid weight loss, and the drugs' effect on gastrointestinal transit time, which can alter how oral medications—including birth control pills—are absorbed. The situation has prompted calls for more rigorous surveillance, updated clinical guidance, and a broader conversation about reproductive health in the era of anti-obesity pharmacotherapy.

The Rise of GLP-1 Drugs

GLP-1 receptor agonists are a class of injectable medications originally developed to improve glycemic control in adults with type 2 diabetes. They mimic the action of glucagon-like peptide-1, a hormone that stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying—producing a feeling of fullness. Over the past five years, several of these drugs have been repurposed and approved for chronic weight management, leading to a surge in prescriptions. Semaglutide, in particular, has become a blockbuster, with millions of people worldwide using it to achieve significant, sustained weight loss.

The public interest has also fueled off-label use and direct-to-consumer demand. In clinical trials, participants often lose 10-20% of their body weight over the course of a year. For many women with obesity, such dramatic weight reduction can have profound hormonal consequences. Adipose tissue produces estrogen, and excess body fat is associated with anovulation—the failure of the ovaries to release an egg. In contrast, weight loss is known to restore ovulatory function in many women, particularly those with polycystic ovary syndrome (PCOS), a leading cause of infertility. The result is that a woman who was previously subfertile due to her weight might suddenly resume regular ovulation, raising her chances of conception even if she was not actively planning a pregnancy.

Doctors note that this is not a direct pharmacological effect of the drug itself, but rather a secondary consequence of metabolic improvement. "GLP-1 agonists do not cause ovulation directly," explains a reproductive endocrinologist at a university medical center who requested anonymity to discuss preliminary observations. "But the weight loss they induce can normalize the hormonal environment, and that can restore fertility in women who had been experiencing irregular or absent menstrual cycles.”

The Birth Control Interaction

A second, more concerning pathway involves the interaction between GLP-1 drugs and oral contraceptives. Delayed gastric emptying—a hallmark effect of GLP-1 receptor activation—slows the movement of food from the stomach to the small intestine. Since oral medications rely on absorption in the gastrointestinal tract, prolonged transit time can theoretically affect their pharmacokinetics. For contraceptive pills, this means that hormone levels in the bloodstream might not reach the steady-state concentrations required to reliably suppress ovulation.

Although the evidence base is limited, many physicians have begun to advise women of childbearing age on GLP-1 therapy to use additional or alternative forms of contraception. “We are seeing enough reports to take this seriously,” says a family medicine specialist who focuses on obesity care. “If a patient is on a combined oral contraceptive, I recommend she consider an intrauterine device or a contraceptive implant, which do not depend on gastric absorption.”

Some health authorities have already updated their prescribing information to reflect these concerns. The European Medicines Agency, for example, issued guidance in 2023 suggesting that oral contraceptives may be less effective in patients treated with GLP-1 receptor agonists, urging clinicians to consider switching to non-oral methods or adding a barrier method during initiation and dose escalation. The U.S. Food and Drug Administration has not yet mandated a labeling change, but independent researchers are analyzing electronic health records to quantify the true incidence of unintended pregnancies among GLP-1 users.

Expert Perspectives and Early Research

Medical experts emphasize that the current reports, while suggestive, do not establish a causal relationship. Unintended pregnancies can occur in any population, and the baseline rate of contraceptive failure—even with perfect use—is not negligible. Moreover, women who are losing weight rapidly may simply feel better and become more sexually active, increasing the opportunity for conception. Without controlled studies, it is difficult to separate the effects of the drug from the behavioral and physiological changes that accompany significant weight reduction.

Nevertheless, specialists in reproductive medicine warn that the potential for GLP-1 therapy to restore fertility has important implications for women who are not ready for pregnancy. Historically, obese women with irregular cycles may have assumed they were infertile, and they might not use contraception consistently. As these women lose weight, their fertility can return quickly—sometimes within weeks—even before menstruation regularizes, making it impossible to predict which cycles are ovulatory.

“This is a hidden blessing for women who are trying to conceive, but a hidden risk for those who are not,” remarks a professor of obstetrics and gynecology who studies drug safety in pregnancy. “We have a global population of patients taking these medications, many of them of reproductive age. The lack of data is concerning.”

Early research from animal studies suggests that semaglutide and related molecules cross the placenta and can cause fetal abnormalities, prompting manufacturers to recommend discontinuation at least 2 months before a planned pregnancy. However, the outcomes of accidental human exposures are not systematically collected, so the true teratogenic risk remains unknown. In the absence of robust evidence, clinicians are advised to counsel patients about the necessity of reliable birth control and to perform pregnancy tests before initiating therapy and at regular intervals thereafter.

Practical Recommendations for Women on GLP-1 Therapy

For women currently taking a GLP-1 medication, healthcare providers are offering a suite of counsel. The first and most important recommendation is not to stop the drug abruptly if pregnancy is discovered, but to contact a doctor immediately to discuss the risks and benefits. Patients who are trying to conceive should be advised that GLP-1 drugs are not considered safe during pregnancy, and they should ideally complete treatment and allow a wash-out period before attempting conception—unless a doctor recommends otherwise.

At the same time, women who definitely wish to avoid pregnancy should be counseled to consider long-acting reversible contraceptives (LARCs), such as hormonal intrauterine systems or subdermal implants, which have failure rates below 1% and are unaffected by gastrointestinal motility. For those who prefer oral pills, a backup method like condoms is advisable, especially during the initial weeks of treatment and after dose increases, when gastric emptying is most delayed.

Another pragmatic clue is to track menstrual patterns. Women who experience a return of regular monthly bleeding after a long period of amenorrhea should be alert to the possibility of regained fertility. Home ovulation prediction kits can also help identify when fertility is most likely. Public health campaigns, however, caution against relying on home testing as a substitute for medical counseling.

What’s Next: Research and Regulatory Action

The medical community is now seeking answers through formal studies. Several academic institutions have launched retrospective analyses of insurance claims and prospective cohort studies that follow women taking GLP-1 medications over time. The goal is to compare pregnancy rates in this population with those in women not using the drugs, while controlling for age, baseline body mass index, and contraceptive preference. These studies are expected to yield preliminary results within a year.

In the meantime, regulatory agencies are monitoring adverse event reports. A spokesperson for the FDA noted that the agency is aware of the emerging safety signal and will review any new data to determine if additional warnings are warranted. In Europe, the European Medicines Agency has advised healthcare professionals to be vigilant and to report any pregnancy occurring during GLP-1 therapy through national pharmacovigilance systems. Advocacy groups for women’s health have also called for clearer labeling and more explicit shared decision-making aids.

For now, the key takeaway for patients and providers alike is that GLP-1 drugs have transformed the landscape of obesity and metabolic care, but they come with consequences that extend beyond the scale. Fertility, contraception, and family planning must be part of any conversation about starting these medications. The unexpected pregnancies reported by women may ultimately lead to a better understanding of how these drugs interact with reproductive physiology—and to safer, more patient-centered care. Until then, the message is clear: life, in more ways than one, can change quickly with a GLP-1 prescription.